Suppr超能文献

秋水仙碱与泼尼松龙治疗复发性阿弗他口炎的比较:一项双盲随机临床试验。

Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial.

作者信息

Pakfetrat Atessa, Mansourian Arash, Momen-Heravi Fatemeh, Delavarian Zahra, Momen-Beitollahi Jalil, Khalilzadeh Omid, Basir-Shabestari Samira

机构信息

Oral Medicine Department, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Clin Invest Med. 2010 Jun 1;33(3):E189-95. doi: 10.25011/cim.v33i3.13725.

Abstract

PURPOSE

Recurrent aphthous stomatitis (RAS) is one of the most common ulcers of the oral cavity with a reported prevalence of 5- 50%. There is still no definitive treatment for RAS; however, immunosuppressive and immunomodulant agents have been proposed. In this study, we compared the therapeutic effects of 5 mg/d prednisolone with 0.5 mg/d colchicine in the treatment of RAS.

METHODS

In a double-blind randomized clinical trial, 34 patients with RAS were randomly divided into two groups for treatment with prednisolone or colchicine. All patients took the medication for three months and were assessed at two weeks intervals. The groups were compared for size and number of lesions, severity of pain and burning sensation, duration of pain-free episodes and any side effects of the prescribed medicines. Both colchicine and prednisolone treatments significantly reduced RAS (p < 0.001). No significant differences in size and number of lesions, recurrence and severity of pain and duration of pain-free period were seen between the two treatment groups. Colchicine (52.9%) had significantly more side effects than prednisolone (11.8%).

CONCLUSION

Low dose prednisolone and colchicine were both effective in treating RAS. Given that the two therapies had similar efficacy, yet colchicine was associated with more side effects, , 5mg/d of prednisolone seems to be a better alternative in reducing the signs and symptoms of the disease.

摘要

目的

复发性阿弗他口炎(RAS)是口腔最常见的溃疡之一,报告患病率为5%-50%。RAS仍无确切的治疗方法;然而,免疫抑制剂和免疫调节剂已被提出。在本研究中,我们比较了5mg/d泼尼松龙与0.5mg/d秋水仙碱治疗RAS的疗效。

方法

在一项双盲随机临床试验中,34例RAS患者被随机分为两组,分别接受泼尼松龙或秋水仙碱治疗。所有患者服药三个月,每隔两周进行评估。比较两组病变的大小和数量、疼痛和烧灼感的严重程度、无痛发作的持续时间以及所开药物的任何副作用。秋水仙碱和泼尼松龙治疗均能显著减轻RAS(p<0.001)。两个治疗组在病变大小和数量、复发情况、疼痛严重程度和无痛期持续时间方面均无显著差异。秋水仙碱(52.9%)的副作用明显多于泼尼松龙(11.8%)。

结论

低剂量泼尼松龙和秋水仙碱治疗RAS均有效。鉴于两种疗法疗效相似,但秋水仙碱的副作用更多,5mg/d泼尼松龙似乎是减轻该病症状的更好选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验